Jacqualyn A. Fouse
Net Worth

Last updated:

What is Jacqualyn A. Fouse net worth?

The estimated net worth of Dr. Jacqualyn A. Fouse is at least $13,540,021 as of 13 Jun 2024. He owns shares worth $4,976,483 as insider, has earned $943,538 from insider trading and has received compensation worth at least $7,620,000 in Agios Pharmaceuticals, Inc..

What is the salary of Jacqualyn A. Fouse?

Dr. Jacqualyn A. Fouse salary is $1,270,000 per year as Chief Executive Officer & Director in Agios Pharmaceuticals, Inc..

How old is Jacqualyn A. Fouse?

Dr. Jacqualyn A. Fouse is 64 years old, born in 1961.

What stocks does Jacqualyn A. Fouse currently own?

As insider, Dr. Jacqualyn A. Fouse owns shares in one company:

Company Title Shares Price per share Total value
Agios Pharmaceuticals, Inc. (AGIO) Chief Executive Officer & Director 137,396 $36.22 $4,976,483

What does Agios Pharmaceuticals, Inc. do?

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO logo
AGIO
Agios Pharmaceuticals, Inc.
$36.22

Jacqualyn A. Fouse insider trading

Agios Pharmaceuticals, Inc.

Dr. Jacqualyn A. Fouse has made 4 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 40,322 units of AGIO stock on 13 Nov 2019. As of 13 Jun 2024 he still owns at least 137,396 units of AGIO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted stock units 3,388 N/A N/A
Option
Common stock 3,388 N/A N/A
Sale
Common stock 7,791 $27.55 $214,642
Option
Restricted stock units 15,934 N/A N/A
Option
Common stock 15,934 N/A N/A
Sale
Common stock 10,722 $21.64 $232,024
Option
Common stock 23,900 N/A N/A
Option
Performance share units 23,900 N/A N/A
Sale
Common stock 8,391 $22.99 $192,909
Option
Performance share units 17,500 N/A N/A
Option
Common stock 17,500 N/A N/A
Sale
Common stock 10,718 $28.36 $303,962
Option
Performance share units 23,900 N/A N/A
Option
Common stock 23,900 N/A N/A
Option
Common stock 15,933 N/A N/A
Option
Restricted stock units 15,933 N/A N/A
Option
Restricted stock units 11,333 N/A N/A
Option
Common stock 11,333 N/A N/A
Option
Performance share units 12,379 N/A N/A
Option
Common stock 12,379 N/A N/A
Option
Common stock 11,334 N/A N/A
Option
Restricted stock units 11,334 N/A N/A
Option
Common stock 11,333 N/A N/A
Option
Restricted stock units 11,333 N/A N/A
Option
Performance share units 12,379 N/A N/A
Option
Common stock 12,379 N/A N/A
Purchase
Common stock 40,322 $31 $1,249,982
Option
Common stock 1,400 N/A N/A
Option
Restricted stock units 1,400 N/A N/A

Agios Pharmaceuticals key executives

Agios Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: